The main diseases and indications treated by mirikizumab

Milikizumab (Mirikizumab) is an interleukin-23 (IL-23) antagonist that mainly treats a variety of diseases related to the immune system by inhibiting the effects of IL-23. IL-23 plays a key role in a variety of immune-mediated inflammatory diseases, especially in inflammatory bowel disease (IBD). Overactivity of IL-23 can exacerbate immune responses and lead to chronic inflammation of the intestine. Militizumab blocks the action of IL-23, thereby effectively slowing down the immune system's overreaction and helping to control the disease.

1. Moderately to severely active ulcerative colitis in adults (UC):

Ulcerative colitis is a chronic inflammatory bowel disease that mainly manifests as chronic inflammation of the large intestine. Patients often experience symptoms such as abdominal pain, diarrhea, and weight loss. Militizumab helps reduce intestinal inflammation, relieve symptoms, and improve patients' quality of life by inhibiting IL-23. It is especially suitable for patients who have poor response or intolerance to conventional drugs (such as aminosalicylic acid, steroid).

2. Moderately to severely active Crohn’s disease (CD) in adults:

Crohn's disease is another chronic immune-mediated intestinal disease that typically manifests as chronic inflammation in the intestines and can affect any part of the digestive tract. People with Crohn's disease may experience severe abdominal pain, diarrhea, weight loss, and intestinal narrowing. By inhibiting IL-23, militizumab can effectively slow down the inflammatory response, promote intestinal healing, and reduce the recurrence of the disease.

Milizumab inhibits the effect of IL-23 on the immune system by binding to the p19 subunit of IL-23. IL-23 contributes to the persistence of inflammation by stimulating the activation of T cells and other immune cells. Therefore, by blocking the action of IL-23, militizumab can significantly reduce the activity of immune cells, thereby reducing the inflammatory response of the disease.

Milizumab's efficacy in treating ulcerative colitis and Crohn's disease is supported by multiple clinical studies and offers a new treatment option compared to traditional treatment options for patients whose conditions are difficult to control.

Keyword tags: Militizumab, ulcerative colitis, Crohn's disease,IL-23 antagonist, immune system, treatment options

Reference materials:https://www.drugs.com/mirikizumab.html